GENFIT S.A. - ADR

Name: GENFIT S.A. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: GENFIT S.A. - ADR

Stock Card

$5.97

$0.00 (0.00%)

As on 21-Jan-2026 09:30EDT

Market cap

$244 Mln

Revenue (TTM)

$112 Mln

P/E Ratio

P/B Ratio

4.9

Div. Yield

0 %

GENFIT S.A. - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 5.97 High: 5.97

52 Week Range

Low: 2.55 High: 7.00

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

20
Debt to Equity

0.9
Book Value

$1.4
EPS

$0
Face value

--
Shares outstanding

50,002,896

10 Years Aggregate

CFO

€-336.22 Mln

EBITDA

€-275.05 Mln

Net Profit

€-357.67 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
GENFIT S.A. - ADR	-2.9	-6.7	46.3	72.0	11.5	1.1	--
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 21-Jan-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020
GENFIT S.A. - ADR	65.5	-3.5	-12.3	-12.2	4.2	-75.9
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About GENFIT S.A. - ADR

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients... with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Read more